Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
Ledermann J, et. al. N Engl J Med. Volume 366:15 (2012): 1382-1392.
Conclusion: Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit.
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Patel AG, et. al. Clin. Cancer Res. Volume 18:6 (2012): 1655-1662.
Conclusion: While iniparib kills normal and neoplastic cells at high (>40 µM) concentrations, its effects are unlikely to reflect PARP inhibition and should not be used to guide decisions about
other PARP inhibitors.
BRCA mutation testing in determining breast cancer therapy
Smith, KL and Isaacs, C. Cancer J. 17(6):2011 Nov-Dec; Pages: 492-499.
This article reviews surgical and treatment options for management of affected BRCA mutation carriers with breast cancer.
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Kaye SB, et. al. J. Clin. Oncol. Volume 30:4 (2012): 372-379.
Conclusion: The efficacy of olaparib was consistent with previous studies. However, the efficacy of PLD (Doxil) was greater than expected. Olaparib 400 mg twice per day is a suitable dose to explore in further studies in this patient population.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Gelmon KA, et. al. Lancet Oncology. Volume 12:9 (2011): 852-861.
Conclusion: Our study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clinical trials is needed.
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
Mark E Robson et. al. Breast Cancer Research. Volume 6:1 2004. Pages R8-R17.
Conclusion: BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy.
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.